Pfizer Inc

NYSE: PFE
$29.22
-$0.05 (-0.2%)
Closing Price on October 18, 2024

PFE Articles

Some moves in the most heavily shorted stocks traded on the New York Stock Exchange were sizable between the March 15 and March 31 settlement dates.
The breakup of the Pfizer-Allergan deal may only be a warning sign for both Apple and Google and any other company filtering money through foreign countries to avoid taxes, but the trend of plugging...
Thursday's top analyst upgrades, downgrades and initiations include Apple, Coach, EMC, Hewlett Packard Enterprise, Pfizer and Verizon.
April 6, 2016: Markets opened higher on Wednesday following mixed trading in Asia. The dollar weakened and the release of the minutes from the FOMC’s March meeting gave equities an additional boost...
The Business Roundtable, the primary representatives of the CEOs of America's largest companies, made a statement about business combinations that involve tax inversions.
After much waiting, the broad markets and the Dow Jones Industrial Average in particular have made it back to positive territory.
ThinkstockApril 1, 2016: Markets opened lower on Friday following the monthly employment report from the Bureau of Labor Statistics. The unemployment rate ticked up to 5% and job growth was slightly...
March 31, 2016: Markets opened higher again on Thursday but only the Nasdaq Composite was able to hold on for a modest gain on the day. The only sector to trade higher for the day was utilities and...
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes...
Interest in almost all of the most heavily shorted stocks traded on the New York Stock Exchange shrank between the February 29 and March 15 settlement dates. Except for Pfizer, that is.
March 21, 2016: Markets opened lower on Monday on some weakness overnight in oil prices. The morning report on existing home sales weighed on equity prices as well. A number of merger announcements...
Pfizer announced the results from its first two pivotal Phase 3 studies from the Oral Clinical Trials for tofacitinib in ulcerative colitis program at the 11th Congress of European Crohn's and...
So what are investors to do in a continued low rate environment? Buy the best stocks out there, especially ones paying good dividends.
One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be removed from the market, creating a huge risk and opportunity in...
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.